An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease

Yoshinobu Maeda, Hisakazu Nishimori, Yoshihiro Inamoto, Hirohisa Nakamae, Masashi Sawa, Yasuo Mori, Kazuteru Ohashi, Shin ichiro Fujiwara, Mitsune Tanimoto

研究成果: Contribution to journalArticle査読

3 被引用数 (Scopus)

抄録

Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.

本文言語英語
ページ(範囲)409-412
ページ数4
ジャーナルActa medica Okayama
70
5
出版ステータス出版済み - 2016

All Science Journal Classification (ASJC) codes

  • 生化学、遺伝学、分子生物学(全般)

フィンガープリント

「An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル